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Understanding the factors that impede immune
responses to persistent viruses is essential in
designing therapies for HIV infection. Mice infected
with LCMV clone-13 have persistent high-level
viremia and a dysfunctional immune response. Inter-
leukin-7, a cytokine that is critical for immune devel-
opment and homeostasis, was used here to promote
immunity toward clone-13, enabling elucidation of
the inhibitory pathways underlying impaired antiviral
immune response. Mechanistically, IL-7 downregu-
lated a critical repressor of cytokine signaling,
Socs3, resulting in amplified cytokine production,
increased T cell effector function and numbers, and
viral clearance. IL-7 enhanced thymic output to
expand the naive T cell pool, including T cells that
were not LCMV specific. Additionally, IL-7 promoted
production of cytoprotective IL-22 that abrogated
liver pathology. The IL-7-mediated effects were
dependent on endogenous IL-6. These attributes of
IL-7 have profound implications for its use as a thera-
peutic in the treatment of chronic viral diseases.
INTRODUCTION
Much attention has focused onmodulating immune responses in
an attempt to promote clearance of chronic viral infections. Thisis particularly relevant to human immunodeficiency virus (HIV)
infections in which the immune system fails to clear virus and
eventually succumbs to uncontrolled viral turnover (Day et al.,
2006; Klenerman and Hill, 2005). Understanding the mecha-
nisms that circumvent immune responses in cases of over-
whelming viral replication and antigen expression underlies any
rational attempt to augment immunity in HIV infection.
Lymphocytic chorimeningitis virus (LCMV) variant clone 13
establishes a chronic infection in mice with high viral turnover,
hence mimicking the massive viral antigen levels associated
with HIV infection in humans (Wherry et al., 2003). Clone 13
infection has served as a powerful tool in characterizing the
dysfunctional immune response associated with chronic
viremia, and numerous parallels with HIV, HCV, and HBV infec-
tion have been described (reviewed in Wilson and Brooks
[2010]). In contrast to clone 13, LCMV Armstrong causes an
acute infection in C57Bl/6 mice, and the immune response
differs significantly from clone 13 infection both in magnitude
and also in the specificity of the responding immunodominant
CD8 T cell clones (Wherry et al., 2003). In Armstrong infection,
the most prominent and highest-affinity CD8 T cell response is
directed against the dominant nucleoprotein NP396 epitope, fol-
lowed by the glycopeptide GP33 epitope and then by GP276.
Clone 13 infection is characterized by a deletion of the high-
affinity NP396 clones and potentially a functional defect in the
remaining LCMV-specific T cells clones (Wherry et al., 2003).
Similar phenotypic and functional disturbances have been
described in T cells of HIV-infected humans (Day et al., 2006).
Several host inhibitory pathways, which may circumvent
effective immune responses, have been identified in mice thatCell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc. 601
are chronically infected with LCMV clone 13 (Barber et al., 2006;
Brooks et al., 2006; Ejrnaes et al., 2006; Matter et al., 2006). We
hypothesized that nonredundant cytokines involved in homeo-
static proliferation, and therefore apt at overcoming inhibitory
networks that naturally limit expansion, would offer the most
promise in promoting immune responses. IL-7 is unique for its
critical and nonredundant role in immune development and
homeostasis and therefore is a prime candidate for use as an
immunotherapeutic to overcome immune inhibitory networks in
chronic active infections. Indeed, IL-7 offers significant thera-
peutic promise (Levy et al., 2009; Sereti et al., 2009; Sporte`s
et al., 2008). It has been used in several nonhuman primate SIV
infection models that have demonstrated its diverse immunolog-
ical effects (Beq et al., 2006; Fry et al., 2003; Nugeyre et al.,
2003). However, the efficacy of IL-7 in promoting viral clearance
has not been fully explored. Importantly, the ability of IL-7 to
antagonize immune inhibitory networks and the mechanism
underlying its immune modulatory actions remains an area of
active investigation. Such knowledge holds the potential to illu-
minate points for rational therapeutic intervention.
In this study, administration of recombinant human IL-7 to
mice that are chronically infected with clone 13 increased the
magnitude of the immune response with rescue of the NP396-
specific T cell clones. It increased the size of the naive T cell
pool, including T cell clones directed against non-LCMV specific
epitopes, in part by increasing thymic output. LCMV clone
13-specific T cells showed enhanced degranulation kinetics
and cytokine production with IL-7 therapy, resulting in effective
viral clearance and a downregulation of PD-1 on effector
T cells. In addition, IL-7 promoted a cytokine milieu favoring
immune activation and production of the cytoprotective cytokine
IL-22, thus limiting hepatotoxicity. At the molecular level, IL-7
downregulated suppressor of cytokine signaling 3 (Socs3)
expression in T cells. This was mediated by suppression of
FoxO transcription factors. We show that conditional deficiency
of Socs3 in T cells replicates aspects of the IL-7-induced pheno-
type inmice that are infectedwith LCMVclone 13. These findings
have major implications for our understanding of chronic viremia
and the therapeutic use of IL-7.
RESULTS
IL-7 Increases Antiviral T Effector Responses andOrgan
Infiltration in Clone 13 Infection
Clone 13-infected mice were treated with IL-7 or PBS
commencing 8 days after infection, when chronicity had been
established. After 3 weeks of IL-7 therapy, the total number of
splenic CD8 and CD4 T cells was increased 11- and 5-fold,
respectively, compared to PBS control animals (Figure 1A).
IL-7 treatment did not alter the number of granulocytes, macro-
phages, or dendritic cells (DCs) compared to controls. A
dramatic 10- to 25-fold increase in virus-specific CD8 T cells
recognizing GP276 and GP33, respectively, was observed in
IL-7-treated mice compared to controls (Figure 1B). An equally
robust 10-fold increase in NP396-specific T cells, which repre-
sented a very small proportion of virus-specific cells in control
animals, was also observed (Figure 1B). The increase in splenic
CD8 and CD4 T cell numbers and virus-specific T cells tracked602 Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc.with an equivalent increase in liver, kidney, brain, and lung infil-
tration by lymphocytes and virus-specific T cells (Figures 1C
and 1D and data not shown). Therefore, IL-7 is able to expand
and rescue T cell numbers, including CD8 T cell clones that
are normally deleted in clone 13 infection, resulting in efficient
lymphocyte infiltration into infected organs.
Enhanced Function of Virus-Specific T Cells,
Viral Clearance, and Downregulation of PD-1
with IL-7 Treatment
To verify that the large increase in clone 13-specific T cells in
IL-7-treated animals translated to a functional gain, we exam-
ined their ex vivo capacity to degranulate and produce cyto-
kines. We observed a 2-fold increase in the proportion of clone
13-specific CD8 T cells in IL-7-treated animals at day 29 postin-
fection that were able to produce cytokines and degranulate in
restimulation assays compared to controls (Figure 2A). This
translates to a massive 30- to 50-fold increase in the number
of functional GP33-specific splenic CD8 T cells in IL-7-treated
animals compared to controls (Figure 2A). Similarly, the propor-
tion of clone 13-specific CD4 T cells recognizing GP61 that
produce both IFNg and IL-2 was 4-fold higher in IL-7-treated
animals compared to controls (Figure 2B). This translates to
a 20-fold increase in the absolute number of functional CD4
T cells recognizing GP61 in the spleens of IL-7-treated animals
(Figure 2B). These results highlight the potent effects of IL-7
treatment on the total number of functional CD8 and CD4
virus-specific T cells in a model of chronic infection.
Recently, high PD-1 levels on T cells from clone 13-infected
animals have been shown to correlate with a dysfunctional
phenotype (Barber et al., 2006). We thus examined the level of
PD-1 expression on both CD8 and CD4 T cells from IL-7- and
PBS-treated animals and observed lower levels of PD-1 on
both CD8 and CD4 T cells expressing this receptor, and hence
activated by antigen, in IL-7-treated animals compared to
controls (Figures 2C and 2D). Furthermore, an acute activation
marker, CD69, was downregulated on PD-1-expressing T cells
from IL-7-treated animals (Figures 2C and 2D). Collectively,
these data indicate that clone 13-specific CD4 and CD8 T cells
in IL-7-treated mice begin to lose their activation phenotype by
day 29 after 3weeks of therapy,most likely due to viral clearance.
Indeed, IL-7 treatment facilitated viral clearance from spleen and
liver by days 22–29 postinfection and resulted in elimination of
virus from chronic reservoirs, including brain, lung, and kidney
between days 36 and day 60 (Figure 2E). Control animals were
not able to clear virus by the end of follow-up at day 60, consis-
tent with previous reports that have demonstrated long-term
chronicity in clone 13-infected mice (Wherry et al., 2003).
CD4 and CD8 T Cells, but Not B Cells, Are Required
for IL-7’s Capacity to Clear Virus
In addition to the expansion of activated T cells, IL-7 caused an
increase in B cell numbers in infected mice. However, propor-
tionally, T cells represented the largest increase in lymphocyte
numbers (Figure S1 available online and Figure 1A). To determine
which of the expanded lymphocyte populations may contribute
to enhanced clearance of virus, we depleted the various subsets
during the course of IL-7 therapy to maintain CD4 or CD8 T cell
Figure 1. IL-7 Augments Antiviral Responses and Organ Infiltration in Chronic Clone 13 Infection
(A) The absolute number of cells was quantified in infected mice. The gray shaded bars indicate duration of IL-7 or PBS therapy. The experiment was repeated
three times, and data was pooled with error bars indicating SEM (n = 12 for each group and time).
(B) The absolute number of LCMV-specific CD8 T cells was quantified by tetramer staining. Data were obtained from four animals in each group and at each time
point. The experiment was repeated three times, and data were pooled with error bars indicating SEM (n = 12 for each group and time).
(C) Immunohistochemistry showing CD4 and CD8 infiltration in liver sections after 3 weeks of IL-7 or PBS therapy in clone 13-infected mice. These sections are
representative of more than 12 analyzed histological specimens.
(D) Number of infiltrating virus-specific CD8 T cells in livers of IL-7- or PBS-treated clone 13-infected animals after 3 weeks of therapy. Bars represent averages
with SEM from data obtained from six mice in each group. The experiment was repeated twice.
See also Figure S1.numbers at the same level as PBS clone 13-infected control
mice (data not shown). Depletion of either CD4 or CD8 T cells
abrogated IL-7’s ability to clear virus (Figure S2).
Similarly, we depleted B cells with an anti-CD20 mAb (Uchida
et al., 2004) during the course of IL-7 treatment (Figure S2A).
Despite this depletion of B cells, the effects of IL-7 on viral clear-
ance were not diminished (Figure S2B). This is consistent with
previous studies showing that B cells play only minor roles in
modulating T cell responses in cases in which there is abundant
antigen (Bouaziz et al., 2007). Our data clearly demonstrate thatIL-7 exerts its effect on viral clearance through the modulation of
T cells rather than B cells. This has important implications in
translating IL-7 therapies to humans, as this cytokine does not
expand B cells in humans (Rosenberg et al., 2006).
IL-7 Expands Non-LCMV-Specific Naive T Cell Numbers
in Clone 13-Infected Mice
We observed that the majority of splenic CD8 T cells in clone
13-infected mice treated with IL-7 or PBS expressed high levels
of CD44 (Figure 3A and data not shown).We speculated that onlyCell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc. 603
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Figure 2. IL-7 Therapy Enhances T Cell Func-
tion and Facilitates Viral Elimination with
Downregulation of PD-1 and Acute Activation
Markers on CD4 and CD8 T Cells
(A) Direct ex vivo degranulation (CD107a) and cyto-
kine production in virus-specific CD8 T cells during
clone 13 infection. Dot plots, gated on CD8 T cells,
are representative of 12 independent analyses per-
formed after restimulation of splenocytes with
cognate peptides or control peptide at the comple-
tion of IL-7 or PBS in vivo treatment. (Right) Bar graph
shows average cell numbers and SEM.
(B) Cytokine production in virus-specific CD4 T cells
during clone 13 infection. Dot plots, gated on CD4
T cells, are representative of 12 independent analyses
performed after restimulation of splenocytes with
cognate peptide at the completion of IL-7 or PBS
in vivo treatment. Averages and SEM, right arrow,
indicate absolute splenic CD4 T cell numbers
secreting both IFN-g and IL-2.
(C and D) Histograms show the expression level of
markers on either CD8+PD-1+ (C) or CD4+PD-1+ (D)
splenic T cells obtained from animals receiving IL-7 or
PBS for 3 weeks. Contour plots and histograms are
representative of more than 12 analyses performed
on independent mice.
(E) Organ viral titers in IL-7- or PBS-treated clone 13-
infected mice. The gray bars represent duration of
therapy, and dotted lines represent the reliable limit
of detection for viral plaque assay. Significance
(p values) was determined using a time to event
analysis and log rank test.
See also Figure S2.a fraction of these cells were actually LCMV specific, and the
remainder were non-LCMV-specific naive T cells that were upre-
gulating CD44 in response to the inflammatory environment. This
was supported, in the case of IL-7-treated animals, by the fact
that only 15% of the expanded CD8 T cell population, most of
which are CD44hi (data not shown) also expressed PD-1, which
represents an antigen-driven activation marker (Figure 3B). To
examine this further, we purified, phenotyped, and quantified
CD8 T cells recognizing non-LCMV-specific epitopes directed
against the SV40 large T antigen and the ovalbumin-derived
SIINFEKL epitope (using pooled SV40/ova tetramers). These
cells were expanded more than 14-fold in IL-7-treated animals
compared to controls, and in both cases, although to a greater
extent with IL-7 treatment, the levels of CD44 were upregulated
on these cells following clone 13 infection (Figure 3C). Consistent
with the fact that these cells were not activated by TCR trig-
gering, as opposed to GP33 virus-specific T cells, there was
minimal or no upregulation of PD-1 expression, hence indicating
their naive origins (Figure 3C). Collectively, these data support
the view that, in addition to expanding the number of activated604 Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc.virus-specific CD8 T cells, IL-7 also greatly
expands the naive T cell pool, including
T cells recognizing nonviral-related epitopes
in chronically infected mice.
A similar finding has been reported with
the use of IL-7 in uninfected humans(Sporte`s et al., 2008), but our data show that these effects are
eminently translatable to chronic viral infections. These findings
have important implications for the use of IL-7 in HIV-infected
patients in which T cells of many different specificities unrelated
to HIV also succumb to the disease (Li et al., 2005; Mattapallil
et al., 2005). It is unlikely that the expansion of naive T cells
contributes significantly to the clearance of virus in our model,
as IL-7 is administered at the peak of immune activation, and
its predominant effect is expansion of activated LCMV-specific
T cells (Figure 3B).
IL-7 Enhances Thymic Output during Chronic Viral
Infection to Expand the Naive T Cell Pool
The expanded naive T cell pool that we observed with IL-7
therapy may be a result of increased thymic output and/or
peripheral expansion. IL-7 is thought to mobilize recent thymic
emigrants from lymphoid tissues and promote thymic egress
(Chu et al., 2004; Sporte`s et al., 2008). However, there is no
detailed analysis of thymic and peripheral effects on recent
thymic emigrants in the setting of chronic viral infection. To
Figure 3. IL-7 Expands the Naive T Cell Repertoire during Chronic Infection
(A) CD44 expression levels on both antigen-activated (PD-1high) and naive CD8 T cells (PD-1low) among total and LCMV-specific cells at the end of 3 weeks of PBS
therapy in LCMV-infected mice.
(B) The number of antigen-activated (PD-1high) and naive (PD-1low) splenic CD8 T cells in IL-7- and PBS-treated clone 13-infected animals is shown. Gray shading
shows the duration of treatment, and points and bars represent averages with SEM from data obtained from nine mice in each group.
(C) Proportion and phenotype of SV40/ova-specific, non-LCMV-reactive CD8 T cells at day 22 postinfection after 2 weeks of IL-7 or PBS treatment. Histograms
and contour plots only showCD8+tetramerhi cells. As controls, CD8 T cells with LCMV specificities harvested from infected animals are shown (right), and nonviral
reactive SV40/ova-specific CD8 T cells from uninfected and untreated mice are shown on the left. Dot plots and histograms are representative of more than six
analyses performed on independent mice. Arrows indicate the average absolute number of SV40/ova-specific CD8 T cells (± SEM) per mouse.address this issue, we utilized Rag-GFP transgenic mice, which
express green fluorescent protein (GFP) under the control of the
rag2 gene locus (Yannoutsos et al., 2001; Yu et al., 1999). Single
positive cells in the thymus and those recently exiting the thymus
silence the rag gene locus, so GFP levels slowly decline with time
and with each division. We analyzed thymic subsets in clone
13-infected mice and found that, although the number of
double-negative thymocytes did not increase with IL-7treatment, the number of both CD8 and CD4 single positive
thymocytes that were GFP bright increased 3-fold (Figure 4A).
These GFP bright cells are most likely in situ derived thymic cells
rather than peripherally expanded recirculating cells, as the latter
should be GFP negative or dull. Notably, these GFP+ cells have
lower levels of GFP than cells in the thymus of naive uninfected
controls and likely represent cells undergoing local thymic
cycling and expansion promoted by IL-7. Therefore, the increaseCell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc. 605
Figure 4. IL-7 Increases Thymic Output
during Chronic Viral Infection and Promotes
Recent Thymic Emigrants in the Periphery
(A) Rag-GFP mice were used to track recent
thymic emigrants. Infected and uninfected mice
were treated with IL-7 or PBS for 5 days (starting
8 days after infection in the former group).
Numbers represent averages and SD of the total
number of GFP+ cells in the thymus that are double
negative (DN), CD4 positive, or CD8 positive as
indicated. Green represents data from infected
IL-7-treated animals, and blue represents data
from infected PBS-treated animals. Data were
collected from four animals in each group, and the
experiment was repeated twice.
(B) Numbers of recent thymic emigrants in the
periphery of naive uninfected mice. Dot plots and
histograms show the number of GFP+ cells (rep-
resenting recent thymic emigrants in Rag-GFP
mice) in the periphery of uninfected mice treated
with PBS or IL-7 for 5 days. Numbers represent
averages and SD of data collected from four
animals in each group, and the experiment was
repeated twice. Red represents data from naive
IL-7-treated animals, and gray represents data
from naive PBS-treated animals.
(C) Numbers of recent thymic emigrants in the
periphery of clone 13-infectedmice. Contour plots
and histograms show the number of GFP+ cells
(representing recent thymic emigrants in Rag-GPF
mice) in the periphery of clone 13-infected mice
treated with PBS or IL-7 for 5 days starting 8 days
after infection. Each histogram corresponds to the
designated gated population shown in the dot
plots (left). Numbers represent averages and SD of
data collected from four animals in each group,
and the experiment was repeated twice. Green
represents data from infected IL-7-treated
animals, and blue represents data from naive
PBS-treated animals. Asterisks represent p values
as indicated.in GFP bright CD8 and CD4 single positive thymocytes may
reflect a simple local thymic proliferation of newly generated
CD8 and CD4 thymocytes. However, it may also be possible
that enhanced thymopoiesis with de novo production of new
single positive cells may contribute to the increased number of
these cells in the thymus. Among the peripheral T cell population,
in both uninfected and clone 13-infected animals, IL-7 increased
the number of CD4 and CD8 single positive recent thymic
emigrants by 3- to 6-fold, respectively (Figures 4B and 4C).
These GFP+ cells were CD44loPD-1lo, indicating that they were
truly naive and recent emigrants to the periphery (Figure 4C).
These data show that IL-7 therapy in the setting of chronic infec-
tion can substantially expand the peripheral T cell pool both
through mechanisms of peripheral homeostasis and enhanced
thymic output.
IL-7 Augments IL-6, IL-12, IL-17, and IFNg Serum Levels
while Limiting TGF-b Levels
We investigated the serum cytokine levels associated with
the increased numbers of lymphocytes in IL-7-treated clone
13-infected mice. We found that the levels of several proinflam-606 Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc.matory cytokines are greatly increased, particularly IL-6, IL-17,
and IFNg in IL-7-treated infected mice (Figure 5A). However,
there was a modest decrease in the levels of TGFb (Figure 5A).
The large increase in IL-17 serum levels likely reflects an
expansion of Th17 cells, which may be a consequence of an
IL-7-induced shift favoring IL-6 levels over TGFb and, in turn,
favoring Th17 over T regulatory (Treg) cell differentiation (Ogura
et al., 2008; Zhou et al., 2008). Interestingly, we observed
a 2-fold increase in IL-10 serum levels at later time points during
IL-7 treatment compared to controls (Figure 5A). Previous work
suggests that IL-10 may abrogate immunity to chronic viruses,
but in the present study, this inhibitory effect is likely over-
shadowed by the 17- to 18-fold increase in proinflammatory
cytokines (Brooks et al., 2006; Ejrnaes et al., 2006). Despite
the dramatic increases in proinflammatory cytokines and the
heavy infiltration seen in organs of IL-7-treated animals (Fig-
ure 1C), we did not observe any significant immune-mediated
pathology such as hepatitis (Figure 5B). Collectively, these
data show that IL-7 promotes a proinflammatory milieu while
limiting cytotoxicity and decreasing the levels of the inhibitory
cytokine TGFb.
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Figure 5. IL-7 Enhances Cytokine
Responses Favoring IL-6, IL-17, and IFNg
Production and Promotes IL-22-Mediated
Cytoprotection
(A) Serum cytokine levels in IL-7- and PBS-treated
clone 13-infected mice. Graphs represent aver-
ages and SD of data collected from 12 mice in
each group. This experiment was repeated three
times. Asterisks represent p values as indicated.
(B) Serum AST and ALT liver enzyme levels in
uninfected and infected mice treated with IL-7 or
PBS. Graphs represent averages and SD of data
collected from 12 mice in each group.
(C) Serum IL-22 levels in IL-7- and PBS-treated
clone 13-infected animals 21 days following
infection. Graphs represent averages and SEM of
data collected from four mice in each group.
(D) Serum AST levels in infected mice treated with
PBS or IL-7 after IL-22 neutralization. Mice were
infected with clone 13 and 8 days postinfection
treated with IL-7 or PBS. On day 21 postinfection,
IL-22-neutralizing mAb was administered, and
serum AST levels were determined the following
day. Graphs represent averages and SEM of data
obtained from four mice in each group. This
experiment was repeated twice.
See also Figure S3.IL-7 Promotes IL-22-Mediated Cytoprotection
during Clone 13 Infection
As a marker of immune-mediated damage and bystander
pathology, we examined serum liver enzyme levels. Clone 13
causes a mild hepatitis, with an elevation of both serum aspar-
tate transaminase (AST) and alanine transaminase (ALT) 8 days
following infection. Compared to controls, IL-7 did not exacer-
bate liver disease, which resolved quickly in all animals (Fig-
ure 5B). IL-6 has been shown to protect hepatocytes from
T cell-mediated injury, and this cytokine is significantly upregu-
lated in IL-7-treated animals (Klein et al., 2005). IL-22 has also
been identified as a cytoprotective cytokine that limits hepato-
toxicity associated with ConA-induced cytokine storms (Ra-
daeva et al., 2004; Zenewicz et al., 2007). We found a 2-fold
increase in serum IL-22 levels in IL-7-treated mice compared
to PBS treatment in clone 13-infected animals (Figure 5C). To
determine whether the high levels of IL-22 in IL-7-treated clone
13-infected animals was responsible for the lack of significantCell 144, 601–613,liver pathology, we utilized anti-IL-22
mAb to neutralize the effect of this
cytokine. Neutralizing IL-22 caused
a significant hepatitis in IL-7-treated
clone 13-infected mice (Figure 5D). This
cytoprotective effect of IL-22 was not
evident in PBS-treated control animals
when IL-22 was neutralized (Figure 5D),
most likely due to the lack of hepatic infil-
tration and the poor cytokine response
associated with chronically infected PBS
treated mice (Figure 1C and Figure 5A).
These data indicate that IL-7 is able tolimit its potential toxicity, which may be secondary to the
augmented cytokine responses, by enhancing IL-22-mediated
cytoprotection.
IL-22 is produced by Th17 cells (Zenewicz et al., 2007),
lymphoid tissue inducer cells (LTi), and a subset of LTi-like cells
in the gut that express the natural cytotoxic receptor NKp46
(reviewed in Colonna [2009]). To determine which cells were
contributing to the increase in IL-22, we first determined whether
this cytokine was locally produced in the liver. We found
that IL-22 levels were 4-fold higher in the liver than in serum of
IL-7-treated clone 13-infected mice (Figure S3A). This indicates
that there is an endogenous source of IL-22 production in
the liver. Major producers of IL-22 in the liver of IL-7-treated
clone 13-infected animals were CD4+CD3+TCRab+ T cells (Fig-
ure S3B and data not shown). Hence, conventional CD4
T cells, similar to those that secrete IL-17 (Figure S3B), are
a significant source of IL-22 in the liver of IL-7-treated clone
13-infected mice.February 18, 2011 ª2011 Elsevier Inc. 607
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Figure 6. IL-7 Decreases the Proportion of
Treg among the Total T Cell Pool, and
Further Depletion of Treg Enhances Some
IL-7 Effects
(A–D) The total number of Treg in spleen (A) and
liver (D) and the number of Treg as a proportion of
total T cells in spleen (B) and liver (D) are repre-
sented as averages and SEM of data obtained
from four mice in each group. Liver Treg numbers
were determined at day 29 postinfection. This
experiment was repeated twice. Typical levels of
CD25 expression on Foxp3+ Treg and non-Treg
CD4 T cells in spleen and liver of PBS- and IL-
7-treated clone 13-infected mice at day 29 post-
infection are shown (C). These contour plots are
representative of more than six analyses per-
formed independently.
(E) Treg were depleted in clone 13-infected
animals by injection of DT at the indicated time
points. Nontransgenic littermate control (DTR)
mice were also injected with DT for comparison.
Total lymphocytes and LCMV-specific T cells were
quantified in the spleens of PBS- and IL-7-treated
animals. Graphs represent averages and SEM of
data obtained from four mice in each group. This
experiment was repeated twice, and asterisks
represent p values as indicated.
(F) Liver enzyme assay in Treg-depleted animals
infected with clone 13. AST levels were measured
at day 22 postinfection after Treg depletion in
clone 13-infected mice treated with PBS or IL-7.
Graphs represent averages and SEM of data ob-
tained from four mice in each group. This experi-
ment was repeated twice.
(G) Serum cytokine levels in Treg-depleted animals
infected with clone 13. Serum cytokine levels were
measured at day 22 postinfection after Treg
depletion in clone 13-infected mice treated with
PBS or IL-7. Graphs represent averages and SEM
of data obtained from four mice in each group. This
experiment was repeated twice.IL-7 Limits T Regulatory Cell Numbers
in Clone 13 Infection
Reports have suggested that IL-7 renders effector cells refrac-
tory to the effects of T regulatory cells (Treg) (Pellegrini et al.,
2009; Ruprecht et al., 2005). We investigated the effects of
IL-7 on Treg physiology in the setting of chronic clone 13 infec-
tion. We found that the absolute number of Treg or Foxp3+CD4+
T cells was increased in the spleen of IL-7-treated clone
13-infected mice compared to controls. However, when
compared to the overall increase in T cell numbers, Treg were
dramatically underrepresented in IL-7-treated animals (Fig-
ure 6A–6D).
To determine the physiological relevance of Treg in the setting
of chronic infection, we utilized BAC-transgenic DEREG mice
that express a diphtheria toxin (DT) receptor-GFP fusion protein
under the control of the foxp3 gene locus (Lahl et al., 2007). This
allowed us to follow and selectively deplete Foxp3+ Treg cells by
DT injection. We were able to efficiently delete GFP+ cells
without overt adverse effect on the animals (data not shown).608 Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc.Clone 13-infected mice treated with PBS did not show any
significant differences in absolute T cell numbers or GP- or
NP-specific T cell numbers after Treg depletion (Figure 6E). Inter-
estingly, IL-7-treated animals showed a 2- to 3-fold increase in
the numbers of CD8-, CD4-, GP-, and NP-specific T cells,
whereas B cell numbers were not affected after Treg depletion
(Figure 6E). In all animals, the depletion of Treg did not cause
short-term immune-mediated pathology, as liver function tests
did not become elevated after depletion (Figure 6F). These
data suggest that, at least in the short term, Treg do not impede
an immune response in chronic clone 13 infection. However,
Treg do partially abrogate IL-7’s ability to expand T cells, but
notably, viral titers in both IL-7- and PBS-treated animals were
not altered in the absence of Treg (data not shown). Because
previous experiments have shown that IL-7 renders T effector
cells refractory to the inhibitory effects of Treg (Pellegrini et al.,
2009; Ruprecht et al., 2005), we postulated that the increase in
T cell numbers observed only in IL-7-treated animals was
perhaps due to the consumption of IL-2 by Treg (Pandiyan
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Figure 7. IL-7 Represses Socs3 Expression
in T Cells, and Conditional Deletion of
socs3Potently Augments Antiviral Immunity
(A) Viral titers performed 3 weeks postinfection in
IL-6-deficient and control mice treatedwith PBS or
IL-7 for 2 weeks starting 8 days after infection.
Error bars represent SEM.
(B) Socs3 expression in T cells from LCMV Arm-
strong and LCMV clone 13-infected animals.
Socs3 protein levels in sorted T cells were deter-
mined by western blot at the indicated time points
after infection.
(C) Expression of Socs3 in splenic T cells from
infected mice treated with IL-7 or PBS in vivo for
5 days. Direct ex vivo western blot analysis was
performed for Socs1 and Socs3 levels. Blots are
representative of three independent experiments.
(D) Socs3 expression levels determined by
western blot in naive T cells isolated from FoxO1/
3/4 conditionally deficient mice or control animals.
(E) Numbers of LCMV clone 13-specific CD8
T cells in control and Socs3 conditionally (MxCre)
deleted mice 6 days post-LCMV clone 13 infec-
tion. Error bars represent SD.
(F) Dot plots showing proportions of NP396-
specific CD8 T cells in Socs3 conditionally
(LckCre) deleted mice and control mice 8 days
after infection.
(G) Numbers of LCMV clone 13-specific CD8
T cells in control and Socs3 conditionally (Lck)
deleted mice 8 days post-LCMV clone 13 infec-
tion. Error bars represent SD.
(H) Ex vivo cytokine production by LCMV clone 13-
specific T cells from indicated mice at day 8
postinfection. Splenocytes were restimulated
in vitro with control (OVA) or cognate (GP61)
peptides to quantify CD4 T cells and GP33 to
quantify CD8 T cells. Phorbol myristate acetate
(PMA) and ionomycin restimulation were used for
the quantification of IL-17-producing CD4 T cells.
Proportions in each quadrant are indicated.
(I) Average numbers of T cells secreting indicated
cytokines in aforementioned assay. Errors bars
represent SD.
(J) Virus titers in the indicated mice and organs on
day 8 (top) and day14 (bottom) postinfection.
See also Figure S4 and Figure S5.et al., 2007). In the absence of Treg, the abundance of this cyto-
kine may further augment the expanded immune response seen
in IL-7-treated animals. Indeed, when we examined the level of
IL-2 compared to other cytokines, it was proportionally
increased in IL-7-treated and Treg-depleted animals compared
to nondepleted animals. This consumption of IL-2 in IL-7-treated
animals is further supported by the high level of CD25 expression
on both Treg and non-Treg CD4 T cell populations at day 29
postinfection (Figure 6C). Our data therefore suggest that deple-
tion of Treg may compliment the effects of IL-7 by removing
a potential cytokine sink.
IL-7 Reprograms T Cells to Repress
Socs3 Inhibitory Pathways
In view of the dramatic increase in numerous cytokine levels
and the ability of IL-7-treated mice to efficiently clear virus, weinvestigated whether inhibitors of cytokine signaling may be
repressed. We focused on Socs3, given its prominent role in
the negative regulation of IL-6 signaling (Croker et al., 2003;
Lang et al., 2003) and prominent increase of this cytokine in
the context of IL-7 treatment. Interestingly, the efficacy of IL-7
in promoting cytokine responses, including IL-22 and T cell
expansion and viral clearance, is diminished in IL-6-deficient
mice (Figure 7A and Figures S4A–S4C). Furthermore, it has
been shown that, in the absence of Socs3, IL-6 signaling is re-
programmed to mimic IFN responses, and this may contribute
to more efficient viral elimination (Croker et al., 2003; Lang
et al., 2003). We first investigated whether Socs3 levels in
T cells are aberrantly upregulated in clone 13 infection compared
to acute LCMV Armstrong infection. Even at very early time
points during clone 13 infection, the levels of Socs3 in T cells,
purified and analyzed directly ex vivo, were substantially higherCell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc. 609
in clone 13-infected mice compared to Armstrong infected
animals (Figure 7B). We then purified total T cells from PBS- or
IL-7-treated clone 13-infected animals. Direct ex vivo western
blot analysis was performed and established that IL-7 treatment
resulted in a substantial reduction in Socs3 levels in T cells (Fig-
ure 7C). We did not observe any differences in Socs1 levels.
These data elucidate a pathway downstream of IL-7 that inter-
feres with Socs3 inhibition of cytokine-mediated signaling.
Socs3 Is Endogenously Regulated by FoxO
Transcription Factors
It is generally accepted that Socs3 is induced with cytokine
signaling via a Stat-dependent pathway. It is unusual then that
IL-7, a potent inducer of Stat5 signaling, is able to repress
Socs3. However, FoxO transcription factors can be negatively
regulated by IL-7 and perhaps other cytokines that signal via
the common g chain receptor (reviewed in Kittipatarin and
Khaled [2007]), and under certain circumstances, Stat5 tran-
scriptional activity may negatively regulate FoxO1 (Stittrich
et al., 2010). Therefore, we tested whether FoxO transcription
factors are involved in Socs3 induction. Mice that had all six
alleles of foxO conditionally targeted (foxO1/3/4) were crossed
to MxCre transgenic mice to generate (foxO1/3/4)fl/flMxCre
animals. These mice were injected with poly I:C to generate
animals that were deficient in FoxO1/3/4 in the hemopoietic
compartment (Paik et al., 2007). T cells were purified from these
animals well before the development of any malignancies or
abnormalities. T cells isolated from animals deficient in FoxO
transcription factors had dramatically reduced levels of Socs3,
as determined by western blot (Figure 7D). Collectively, these
data indicate that IL-7 may repress Socs3 expression via inhibi-
tion of FoxO transcriptional activity.
Mice Conditionally Deficient in Socs3 Mimic
the IL-7-Induced T Cell Phenotype in Clone
13-Infected Animals
To assess whether a deficiency in Socs3 in T cells could replicate
some of the IL-7-induced effects that we observed in clone
13-infected animals, we used mice that had socs3 conditionally
targeted (Croker et al., 2003). These socs3fl/flmice were crossed
with MxCre transgenic mice, and gene deletion throughout the
hemopoietic compartment was induced by clone 13 infection,
which induces a type I IFN response and activation of the IFN-
responsive Mx1 promoter. Ex vivo analysis by PCR confirmed
that socs3 was deleted in purified peripheral T cells by day 3
postinfection (data not shown). By day 6 postinfection, all mice
had to be euthanized due to severe illness. At this time point,
Socs3fl/flMxCre+ mice had a 2.5-fold increase in the number of
splenic GP33-specific CD8 T cells and a 6-fold increase in the
number of NP396-specific CD8 T cells compared to control
animals (Figure 7E). Ex vivo analysis of Socs3fl/flMxCre+
GP33-specific CD8 T cells at day 6 postinfection demonstrated
a 5.5-fold increase in the ability of these cells to secrete both
IFN-g and TNF-a compared to controls (Figure S5A). Clone
13-infected Socs3fl/flMxCre+ mice had a dramatic neutrophilia
with a 3.5-fold increase in the number of splenic granulocytes
(Figure S5B). This substantial neutrophilia, which is likely due
to Socs3 deficiency in granulocytes induced by clone 13 infec-610 Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc.tion,may explain the illness that themice succumb to. Liver func-
tion tests indicated a prominent hepatitis in clone 13-infected
Socs3fl/flMxCre+ mice compared to controls (Figure S5C). The
exact cause of lethality in clone 13-infected Socs3fl/flMxCre+ is
not clear but likely relates to the severe granulocytosis observed
in these animals. To avoid the development of granulocytosis
and early lethality, we next used Socs3fl/flLckCre+mice to specif-
ically delete socs3 in T cells.
T Cell-Specific Deletion of socs3 Augments Immunity
to Efficiently Eliminate Virus
Analysis of Socs3fl/flLckCre+ mice on day 8 post-LCMV clone 13
infection showed a profound augmentation of immunity, with
a 15-fold increase in the number of NP396 virus-specific CD8
T cells compared to controls (Figures 7F and 7G). These mice
did not develop a granulocytosis postinfection (Figure S5D)
and showed no signs of increased collateral liver pathology (Fig-
ure S5C), morbidity, or mortality compared to control animals.
Ex vivo analysis of T cells from Socs3fl/flLckCre+-infected mice
at day 8 postinfection showed a 4-fold increase in the ability of
virus-specific CD4 T cells to secrete TNF-a and/or IL-2,
a 7-fold increase in the ability of virus-specific CD8 T cells to
secrete IFN-g, and a 17-fold increase in the number of Th17 cells
(Figures 7H and 7I). The severe granulocytosis and early
mortality in LCMV clone 13-infected Socs3fl/flMxCre+ mice
prevented the elimination of virus, but Socs3fl/flLckCre+ LCMV-
infected mice progressively and efficiently cleared virus from
organs with no mortality (Figure S5E, Figure 7J, and data
not shown). Consistent with viral clearance, we observed
a contraction of the immune response at day 14 postinfection
in Socs3fl/flLckCre+ mice (Figures S5F and S5G). However,
a 3-fold increase in the number of residual high-affinity NP396
virus-specific CD8 T cells persisted in Socs3fl/flLckCre+ mice
compared to controls at day 14 postinfection. (Figure S5G).
These data indicate that the T cell-intrinsic Socs3 induction is
a major factor contributing to immunological failure in the setting
of chronic active infection.
DISCUSSION
Utilizing the clone 13 model, we have shown that IL-7 is able to
overcome many of the factors that thwart an effective immune
response during chronic overwhelming viremia. One host inhib-
itory pathway that may restrict immune responses involves the
Socs family of proteins that critically regulate cytokine signaling.
Socs3 has been identified as the major regulatory molecule that
dampens IL-6 signaling (Yoshimura et al., 2007). Indeed, studies
have shown that the pattern of gene expression induced by IL-6
in Socs3-deficient animals mimics that induced by IFN-g (Croker
et al., 2003; Lang et al., 2003). We have shown that IL-7 is able to
downregulate Socs3 levels in T cells, and additionally, it
promotes IL-6 production. Together, this would reprogram cells
to promote an IFN-like response and facilitate viral clearance.
Furthermore, Socs3 has recently been reported to function as
an intrinsic negative regulator of T cell proliferation (Brender
et al., 2007). Thus, by repressing Socs3, IL-7may promote innate
antiviral mechanisms and also promote expansion and function
of the adaptive immune response.
We found that T cells in clone 13-infected mice have much
higher levels of Socs3 protein compared to T cells from LCMV
Armstrong-infected animals. The importance of both IL-6
and Socs3 repression in mediating the therapeutic potential of
IL-7 was evidenced by the reduced efficacy of IL-7 therapy in
IL-6-deficient animals. We were able to delete socs3 throughout
the hemopoietic compartment of gene-targeted mice contem-
poraneously with clone 13 infection to avoid potential develop-
mental confounders and found that many of the effects that we
observed with IL-7 therapy were replicated in this system. The
MxCre transgene was useful in our studies to coincide the dele-
tion of socs3with the time of infection, but the neutrophilia asso-
ciated with broad deletion of socs3 across the hematopoietic
lineage was associated with early lethality. This adverse event
requires further investigation in the future. Notably, IL-7 does
not induce a granulocytosis, as its effects are limited to cells
that express IL-7R, and hence its ability to repress Socs3 would
be restricted to T cells and perhaps other immune cell subsets,
but not neutrophils. We observed a dramatic increase in LCMV
clone 13-specific immune responses and viral clearance in
mice lacking Socs3 just in T cells. Importantly, these mice
showed no signs of increased collateral damage or pathology
compared to controls. The ability of IL-7 to repress Socs3 in
T cells and perhaps other IL-7 responsive cells has significant
implications for its use in manipulating innate and adaptive
responses to favor elimination of pathogens.
Despite the large increase in cytokine levels and the marked
infiltration of lymphocytes in organs of clone 13-infected animals
receiving IL-7 therapy, we found no significant indication of
bystander hepatitis. We have shown that IL-7 favors in vivo
Th17 differentiation with IL-17 production. This may be due
to IL-7-induced repression of Socs3 and promotion of an IL-
17-IL-6 feedback loop (Ogura et al., 2008). Th17 and other cells
have been identified as a major source of IL-22 (Colonna, 2009;
Ouyang et al., 2008), which is critically important in protecting
hepatocytes and perhaps other cells from immune-mediated
bystander damage (Aujla et al., 2008; Laurence et al., 2008;
Radaeva et al., 2004; Sugimoto et al., 2008; Zenewicz et al.,
2007; Zheng et al., 2008). Indeed, in our clone13model,we found
that IL-7 promotes IL-22 production, and this mitigates collateral
liver damage. These findings are particularly pertinent to the use
of IL-7 in chronic viral hepatitis. In HIV infection, IL-7 also holds
much promise. Systemic immune activation is a hallmark of HIV
disease that has been attributed to circulating microbial prod-
ucts, which may be a consequence of bacterial translocation
across damaged gut mucosa (Brenchley et al., 2006). Endoge-
nous production of IL-22 has been shown to protect mucosal
sites (Aujla et al., 2008; Sugimoto et al., 2008; Zheng et al., 2008).
Another limitation of the immune system in HIV infection is the
inability to replete peripheral losses due to attrition of T lympho-
cytes caused by the virus itself or by secondary effects due to
the high level of viremia (Chase et al., 2006). During clone 13
infection, this is most apparent with the deletion of NP396-
specific T cell clones. IL-7 significantly increased the number
of these clones, but there was also a more general increase in
non-LCMV-specific CD4 and CD8 T cells. Additionally, IL-7
promoted thymic output and substantially expanded the naive
T cell pool in infected mice.Our data provide insights into the inhibitory pathways that
function to impede immune responses in chronic infection. We
elucidate amolecular mechanismwhereby IL-7 is able to repress
Socs3 levels in immune cells to promote extensive expansion of
naive and effector T cells. Furthermore, we highlight the attri-
butes of IL-7 in augmenting recent thymic emigrants in the
face of persistent infection and its ability to promote IL-22
production and hence limit bystander cytotoxicity. Our data
suggest that IL-7 therapy may be a useful adjuvant in chronic
viral diseases like HIV. Antiretroviral therapy is successful in
reducing viral loads to undetectable levels, and in this setting,
T cells become more responsive to IL-7 through the restoration
of IL-7R, thereby enabling their rescue. In this context of reduced
viral load, IL-7 therapy can be used to produce and expand
specific T cells and promote a broad and durable immune-
mediated antiviral response. Furthermore, the secondary cyto-
protective effects of IL-7 have therapeutic implications for the
management of hepatitis C virus infections.
EXPERIMENTAL PROCEDURES
Mice and Viral Infection
The source and/or derivation of mice and viruses is detailed in the Extended
Experimental Procedures. Infection was initiated by injecting 2 3 106 PFU
LCMV clone 13 into the tail vein of 4 to 5-week-old mice. Institutional Animal
Ethics and Care Committees at the Princess Margaret Hospital and the Walter
and Eliza Hall Institute approved all experiments. Procedures complied with
Institutional Animal Care regulations, as detailed in the Extended Experimental
Procedures.
IL-7 Treatment
Eight days after infection, mice were injected subcutaneously once daily
with 10 mg of recombinant human IL-7 or PBS for 3 weeks. Recombinant
CHO cell-derived human IL-7 was provided by Cytheris Inc. (Issy les Mouli-
neaux, France).
Histology and Flow Cytometry
Immunohistological staining has been previously described (Nguyen et al.,
2002). Detailed protocols for the isolation, staining, and in vitro restimulation
of lymphocytes are provided in the Extended Experimental Procedures.
Viral Titer Assays
Organs were homogenized using the QIAGEN TissueLyser, and viral titers
were quantified by focus-forming assays usingMC57 fibroblast cells, as previ-
ously described (Battegay et al., 1991).
Analysis of Transgenic RAG-GFP Mice
Transgenic animals were infected with clone 13 and treated with IL-7 or PBS
8 days after infection, as described above. After 5 days of treatment, thymic
and splenic T cells were isolated, stained, and analyzed for GFP expression
by flow cytometry.
Serum Cytokine Assays
Serum cytokine levels were assayed using the SearchLight Array (Pierce
Biotechnology, Woburn, MA). IL-22 was measured using a quantikine
immunoassay kit (R&D Systems).
Cell Depletion and Cytokine Neutralization
Detailed protocols for cell depletion, including Treg depletion, and IL-22 in vivo
neutralization are provided in the Extended Experimental Procedures.
Liver Enzyme Assays
Serum was analyzed for AST and ALT levels (Vita-Tech Canada).Cell 144, 601–613, February 18, 2011 ª2011 Elsevier Inc. 611
Western Blots
Direct ex vivo analysis of protein expression levels in specific cell populations
is described in the Extended Experimental Procedures.
Statistical Analysis
Animal cohorts used in treatment arms were designed to contain an equal
distribution of sexes. An unpaired two-tailed Student’s t test was used to
determine the statistical significance of observed differences between groups.
Data were analyzed as continuous variables with a normal distribution. A time
to event analysis and log-rank tests were performed on viral clearance
kinetics. Analysis of variance was used for comparisons involving more than
two groups.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2011.01.011.
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